Zanubrutinib for chronic immune low platelets after prior treatments
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and have a diagnosis of immune thrombocytopenia (ITP) based on the study’s criteria.
- Your ITP has been going on for more than 3 months, and you still have low platelets (less than 30) at study entry.
- You have already tried steroid treatment and did not respond or relapsed, and you also had at least one “second-line” treatment that included rituximab more than 12 weeks ago and/or a TPO-RA medicine (like romiplostim or eltrombopag).
- Your liver and kidney tests are within acceptable limits, and you can complete required checkups.
- You must not have certain active infections (including hepatitis B, hepatitis C, and HIV) and must not have serious uncontrolled organ problems, uncontrolled bleeding, or severe heart rhythm/heart control issues.
- You should not be pregnant or breastfeeding, and you must be able to sign informed consent and follow study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
This study tests different doses of a drug called zanubrutinib (a BTK inhibitor) to find the best dose for adults with newly diagnosed ITP that hasn't been treated yet. It aims to see if this drug can safely boost platelet counts and reduce bleeding symptoms.
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.